first intelligent personal nicotine management vaporizer

[ad_1]

After several years of research and development, the start-up Enovap launches on the market the first intelligent personal vaporizer for nicotine management. Discovery.

According to a study by researchers from Queen Mary University of London published on January 30, 2019 in the New England Journal of Medicine the electronic cigarette is twice as effective as conventional nicotine substitutes (patch, sucking tablet, gum chewing…) in the context of a smoking cessation. In fact, a year after the start of weaning, 18% of patients who quit smoking with the help of electronic cigarettes are still abstinent, compared with only 9.9% of people who quit with the help of a nicotine replacement classic.

However, this study notes that 80% of people who have quit smoking still use their electronic cigarette and are by definition still addicted to nicotine. Thanks to its double tank and its artificial intelligence, Enovap fully responds to this double challenge: that of smoking cessation and nicotine addiction.

"Smoking kills 6 million people a year worldwide. Enovap is now taking part in this public health issue, convinced that the smart electronic cigarette can help smoking cessation and that it is one of the solutions of the future. It is indeed a question of proposing a new way of weaning by leaving the possibility to the former smoker to maintain the pleasure of smoking thanks to vaping.Said Alexandre Scheck, CEO of Enovap.

Enovap technology aims to help smokers quit with pleasure and ease through an intelligent nicotine management system. Enovap is a personal vaporizer that gives control to its user, thus offering a real innovative experience. Its artificial intelligence makes it possible to anticipate needs and adapt to any time of the day.

Nicotine requirements vary throughout the day. Thanks to its double reservoir, Enovap gives precise control over the delivery of nicotine to its user. With Hit Control technology, it is possible to vary the nicotinic concentration from 18 mg to 0 mg instantly at the touch of a button, without changing the liquid. The Hit Control thus makes it possible to find a large part of the sensations linked to the consumption of tobacco and therefore to facilitate its cessation.

Thanks to its intelligent learning algorithms, Enovap supports its consumer in a process of nicotine reduction. The device learns from its user's habits, to deliver the optimal amount of nicotine at all times, while decreasing the delivery from day to day. Enovap thus becomes the first nicotine withdrawal e-device.

With its double tank, Enovap offers the Flavor Mix, which allows two flavors to be mixed in proportions chosen by the consumer, in order to obtain the desired flavor cocktail.

Thanks to the application that accompanies the personal vaporizer, the user can monitoring their consumption, activate the automatic reduction mode and thus offer the best possible experience in order to quit tobacco and nicotine step by step.

Enovap technology is based on 100% French know-how. It was designed in collaboration with expert tobacco specialists and vapers. The patented device is based on several functions, each of which encourages people to quit smoking.

The Enovap system uses two modes:

  • The manual mode aimed at stopping smoking: it allows the user to manually adjust the nicotine concentration with each inhalation in order to reproduce the sensations linked to smoking.

  • The automatic reduction mode: when the user has stopped smoking, the automatic reduction mode aims to quit nicotine in the long term. An Enovap mobile application is available in these two modes of use to reinforce the motivation of the user in his withdrawal project and control the AI ​​of automatic mode

Enovap and the CNRS, a linked partnership for AI serving nicotine withdrawal

In order to strengthen the efficiency of its system, Enovap has initiated a partnership with LIMSI, a computer laboratory for mechanics and engineering sciences belonging to the CNRS. This collaboration aims to develop a new artificial intelligence and to develop a real support platform for smoking cessation. For Alexandre Scheck: “Ultimately, and thanks to LIMSI's skills in machine learning, this artificial intelligence will be able to develop, independently, new weaning methods adapted to each one”. The project is supervised by Mehdi Ammi, engineer in electronics, doctor in robotics and qualified to direct research in Human-Machine interaction (IT), within LIMSI.

The algorithm implemented by LIMSI makes it possible to predict in real time the most suitable nicotinic concentration for the user, according to the date, time, day of the week (known by the Enovap device at any time) as well as possibly other data that the device obtains in real time.

" At any time, a user's mobile application can decide to execute the algorithm, which will take into account their new consumption data and annotations and generate a new formula Explains Mehdi Ammi. " In this way, the more the user consumes and therefore creates data, the more the algorithm will be able to generate an effective formula. », Indicates Alexandre Scheck.

Predictive modeling of nicotine consumption is at the heart of the project. It is carried out according to the profile and personality traits of the user, the history of cigarette use and daily physical activity. " It is based on machine learning and statistical processing tools, but also on data fusion strategies and tools for taking into account measurement uncertainties. "Concludes Mehdi Ammi.

Enovap will conduct a 12-month observational study in 2019 in partnership with the Center for Care, Support and Prevention in Addictology (CSAPA) Victor Segalen (Association Hôpital Nord 92) and INSERM, with the support of Dr Anne Borgne, Addictologist at CSAPA Victor Segalen (Association Hôpital Nord 92) and President of Respadd (Network of Health Establishments for the Prevention of Addiction), Dr Marie Bejot, tobacco specialist and Dr Laurent Toubiana PhD epidemiologist at INSERM. The purpose of this study is to validate the effectiveness of the Enovap personal vaporizer for stopping tobacco and then nicotine and to analyze the consumption profile of smokers using the device's smart health connected application.

Enovap is available at a price of € 129 including VAT on the brand's website and in 200 stores in France.

Source: Enovap

Similar articles

[ad_2]